Quadrant Capital Group LLC Syndax Pharmaceuticals Inc Transaction History
Quadrant Capital Group LLC
- $1.42 Billion
- Q3 2024
A detailed history of Quadrant Capital Group LLC transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Quadrant Capital Group LLC holds 2,679 shares of SNDX stock, worth $36,970. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,679
Previous 2,492
7.5%
Holding current value
$36,970
Previous $51,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding SNDX
# of Institutions
229Shares Held
88.4MCall Options Held
1.01MPut Options Held
692K-
Black Rock Inc. New York, NY7.91MShares$109 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ5.84MShares$80.6 Million9.23% of portfolio
-
Wellington Management Group LLP Boston, MA4.99MShares$68.8 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.89MShares$67.4 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY4.11MShares$56.7 Million6.25% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $781M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...